Zealand Pharma A/S became profitable in 2011 as its lead product for Type 2 diabetes reached the registration stage.The Danish enzyme-oriented biotech reported a 94% rise in revenue and other operating income to DKK 171 million and a 12.8% decline in operating expenses.
